

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Catalano et al. Confirmation No. 2460
Application No.: 10/501,636 Art Unit: 1626
Filed: July 15, 2004 Examiner: Rei Tsang Shiao
For: CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS
 CATHEPSIN K INHIBITORS

Customer No.: 23347

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT


Sir:

This paper is submitted in response to the Office Action mailed September 18, 2006. Early examination of the application on the merits is earnestly solicited.

The Examiner has restricted the claims of the present patent application into five groups. In addition, the Examiner has required the Applicant to pick a single species for search purposes. Applicants elect the claims of Group I for prosecution in the present application, and further elect the species shown in Example 3 (Benzyl (2S)-2-{[(3S)-3-({[(1-benzylcyclopentyl)oxy]carbonyl}amino)-2-oxoheptanoyl]amino}propanoate) for purposes of the search. In the accompanying preliminary amendment, applicants have amended the claims to conform with the restriction requirement.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Kathryn L. Coulter
Attorney for Applicants
Registration No. 45,889

Date: 11/9/2006

GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park, North Carolina 27709
Telephone: (919) 483-1467
Facsimile: (919) 483-7988